- Home
- HSBC vs AZN Comparison
HSBC vs AZN Comparison
Compare HSBC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSBC
- AZN
- Stock Information
- Founded
- HSBC 1865
- AZN 1992
- Country
- HSBC United Kingdom
- AZN United Kingdom
- Employees
- HSBC N/A
- AZN N/A
- Industry
- HSBC Savings Institutions
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- HSBC Finance
- AZN Health Care
- Exchange
- HSBC Nasdaq
- AZN Nasdaq
- Market Cap
- HSBC 180.3B
- AZN 205.5B
- IPO Year
- HSBC N/A
- AZN 1993
- Fundamental
- Price
- HSBC $59.25
- AZN $72.83
- Analyst Decision
- HSBC Buy
- AZN Strong Buy
- Analyst Count
- HSBC 1
- AZN 5
- Target Price
- HSBC N/A
- AZN $92.33
- AVG Volume (30 Days)
- HSBC 1.4M
- AZN 5.0M
- Earning Date
- HSBC 04-29-2025
- AZN 07-24-2025
- Dividend Yield
- HSBC 5.53%
- AZN 2.12%
- EPS Growth
- HSBC N/A
- AZN 22.71
- EPS
- HSBC 1.08
- AZN 4.97
- Revenue
- HSBC $57,994,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- HSBC $9.65
- AZN $9.56
- Revenue Next Year
- HSBC $1.20
- AZN $6.09
- P/E Ratio
- HSBC $10.43
- AZN $28.82
- Revenue Growth
- HSBC 2.38
- AZN 15.48
- 52 Week Low
- HSBC $39.42
- AZN $61.24
- 52 Week High
- HSBC $61.88
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- HSBC 61.43
- AZN 61.90
- Support Level
- HSBC $58.57
- AZN $69.97
- Resistance Level
- HSBC $59.36
- AZN $71.41
- Average True Range (ATR)
- HSBC 0.54
- AZN 1.22
- MACD
- HSBC -0.07
- AZN 0.42
- Stochastic Oscillator
- HSBC 59.57
- AZN 94.74
About HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in around 60 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.